VANCOUVER, British Columbia, December 12, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “company“) INM, a leader in the pharmaceutical research, development and manufacture of rare cannabinoids and cannabinoid analogues, today announced that it has entered into a service agreement (the “Agreement”) with Brio Financial Group (“Brio”) to provide senior Financial management and accounting to undertake services. Under the terms of the agreement, Mr. Jonathan Tegge, a member of Brio, will assume the role of interim Chief Financial Officer for the Company effective December 12, 2022.

Brio is a financial and management consulting group based in Bridgewater, New Jersey. The company provides outsourced financial management and financial reporting support to small and medium-sized businesses. The team currently provides consulting services to over 50 private and public companies.

In addition, the Company announces that its auditor, KPMG LLP (“KPMG”), has resigned effective December 8, 2022 and that the Audit Committee of the Company’s board of directors has approved the engagement of Marcum LLP (“Marcum”). ) as auditor, subject to Marcum’s completion of their client acceptance procedures. Marcum will stand for election at the Company’s annual general meeting currently scheduled for Thursday, December 15, 2022 (the “Meeting”). KPMG has confirmed that there were no reportable events (as defined in National Instrument 51-102 – Ongoing Disclosure Requirements (“NI 51-102”)).

Eric A. Adams, Chief Executive Officer of InMed, commented, “We are pleased to hire Marcum as the firm’s new auditor. We believe Marcum’s broad expertise and focus on mid-market companies, including cross-border operations, makes Marcum well-placed to support our efforts to deliver the high levels of financial transparency and reporting that our shareholders are accustomed to.”

InMed has provided KPMG with a copy of Form 8-K in which its…